Last reviewed · How we verify
Rifamycin-free regimen
A tuberculosis treatment regimen that excludes rifamycin antibiotics, typically using alternative agents such as fluoroquinolones, bedaquiline, or linezolid to treat drug-resistant TB.
A tuberculosis treatment regimen that excludes rifamycin antibiotics, typically using alternative agents such as fluoroquinolones, bedaquiline, or linezolid to treat drug-resistant TB. Used for Drug-resistant tuberculosis (MDR-TB or XDR-TB) with rifamycin resistance or intolerance, Tuberculosis in patients with contraindications to rifamycin use.
At a glance
| Generic name | Rifamycin-free regimen |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Antituberculous combination regimen |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Rifamycin-free regimens are designed for patients with TB strains resistant to rifamycin drugs (e.g., rifampicin) or for those who cannot tolerate rifamycins due to adverse effects or drug interactions. These regimens substitute rifamycins with other bactericidal or bacteriostatic agents that target mycobacterial cell wall synthesis, protein synthesis, or energy metabolism to achieve mycobacterial killing without relying on the rifamycin class.
Approved indications
- Drug-resistant tuberculosis (MDR-TB or XDR-TB) with rifamycin resistance or intolerance
- Tuberculosis in patients with contraindications to rifamycin use
Common side effects
- Peripheral neuropathy
- Hepatotoxicity
- QT prolongation
- Gastrointestinal disturbances
- Anemia
Key clinical trials
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
- The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study (PHASE4)
- Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifamycin-free regimen CI brief — competitive landscape report
- Rifamycin-free regimen updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI